Tardive Dyskinesia: Placing Vesicular Monoamine Transporter Type 2 (VMAT2) Inhibitors into Clinical Perspective
Psychiatry and Behavioral Sciences
INTRODUCTION: Tardive dyskinesia (TD) is an iatrogenic movement disorder caused by exposure to dopamine receptor blocking agents. Two vesicular monoamine transporter type 2 (VMAT2) inhibitors for the treatment of TD were approved by the US Food and Drug Administration in 2017: valbenazine and deutetrabenazine. Areas covered: A brief review of TD and its identification, as well as a review of older treatment interventions is provided, followed by a detailed synthesis regarding the clinical utility of valbenazine and deutetrabenazine. Expert commentary: As evidenced from well-designed clinical trials, both valbenazine and deutetrabenazine are efficacious and tolerable. They differ in terms of labeled instructions for frequency of administration (twice daily for deutetrabenazine vs. once daily for valbenazine), titration requirements (dose to efficacy/tolerability for deutetrabenazine vs. titrate to target dose of 80 mg/day for valbenazine), need for food (administer deutetrabenazine with food), drug-drug interactions (consider CYP2D6 modulators for deutetrabenazine vs. both CYP2D6 and CYP3A4 for valbenazine), contraindications (hepatic impairment for deutetrabenazine), and minor differences in adverse event profile.
Citrome, L. (2018). Tardive Dyskinesia: Placing Vesicular Monoamine Transporter Type 2 (VMAT2) Inhibitors into Clinical Perspective. Expert Review of Neurotherapeutics, 18 (4), 323-332. https://doi.org/10.1080/14737175.2018.1455504